Rosenthal G A, Quinto J, Kao J, Rotstein O D
Department of Surgery, University of Toronto, Toronto Western Hospital, Ont.
Can J Surg. 1988 Mar;31(2):98-100.
Fibrin deposition during secondary peritonitis predisposes to abscess formation by protecting bacteria from host-defence mechanisms. To test the hypothesis that local fibrinolytic therapy can prevent the formation of intra-abdominal abscess, daily injections of the fibrinolytic enzymes trypsin and tissue plasminogen activator (t-PA) were administered intraperitoneally to Wistar rats inoculated intraperitoneally with infected fibrin clots. After 5 days, trypsin (1 mg/ml) had significantly (p less than 0.001) reduced abscess formation in animals inoculated with monomicrobial Bacteroides fragilis clots (20% versus 87%) or mixed Escherichia coli-B. fragilis clots (11% versus 91%). Bacteroides fragilis abscesses were also completely prevented with t-PA (0.25 mg/ml). The number of B. fragilis organisms present in residual abscesses in the trypsin-treated group was significantly (p less than 0.05) lower than in the control group (8.2 +/- 0.2, n = 7 versus 5.7 +/- 1.4, n = 4, log CFU/g abscess). In-vitro studies demonstrated that trypsin had no bactericidal effect on B. fragilis, suggesting enhanced clearance of bacteria. From these studies it appears that controlled fibrinolysis at operation may be a useful adjunct to surgery and systemic antibiotics in preventing abscess formation postoperatively.
继发性腹膜炎期间的纤维蛋白沉积通过保护细菌免受宿主防御机制的影响而易于形成脓肿。为了检验局部纤维蛋白溶解疗法可预防腹腔内脓肿形成这一假说,每天向经腹腔接种感染性纤维蛋白凝块的Wistar大鼠腹腔内注射纤维蛋白溶解酶胰蛋白酶和组织型纤溶酶原激活剂(t-PA)。5天后,胰蛋白酶(1mg/ml)显著(p<0.001)减少了接种单一脆弱拟杆菌凝块(20%对87%)或混合大肠杆菌-脆弱拟杆菌凝块(11%对91%)的动物中的脓肿形成。t-PA(0.25mg/ml)也完全预防了脆弱拟杆菌脓肿。胰蛋白酶治疗组残留脓肿中存在的脆弱拟杆菌数量显著(p<0.05)低于对照组(8.2±0.2,n=7对5.7±1.4,n=4,log CFU/g脓肿)。体外研究表明,胰蛋白酶对脆弱拟杆菌无杀菌作用,提示细菌清除增强。从这些研究看来,术中控制性纤维蛋白溶解可能是手术和全身应用抗生素预防术后脓肿形成的有用辅助手段。